Entegris Inc vs Eli Lilly And Co — how do they compare? Entegris Inc trades at $157.74 (market cap $22.95B), while Eli Lilly And Co trades at $1,207.17 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 47.1× Entegris Inc's market cap, and Eli Lilly And Co pays the higher dividend (0.57%). Which is the better fit depends on your goals.
| ENTG | LLY | |
|---|---|---|
Market Cap | $22.95B | $1.08T |
Sector | Technology | Health |
52-Week High | $184.00 | $1.24K |
52-Week Low | $68.80 | $639.43 |
Enterprise Value | $26.16B | $1.13T |
Dividend Yield | 0.27% | 0.57% |
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $144.21, down 5.17% over 24 hours, with a bullish technical outlook from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with $0.93 EPS, driven by AI-related semiconductor demand. Financials show a net income margin of 9.18% and positive operating cash flow of $695.40M in 2025, though valuation ratios like a P/E of 75.11 appear elevated.
Outlook remains positive due to robust earnings growth and AI tailwinds, but high valuation and competitive pressures pose risks. Analyst consensus is bullish with a $188.67 price target, suggesting 31% upside, supported by institutional buying interest and strong media sentiment from recent news highlights.
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
Trailing returns across standard periods
Latest headlines on both assets
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →